Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: Post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphoma

Affiliations

• ¹ Hôpital Saint Louis, APHP, Inserm U976, Université Paris Cité, Paris, France.
• ² Hospices Civils de Lyon, Claude Bernard Lyon 1 University, Lyon, France.
• ³ Department of Malignant Hematology, Moffitt Cancer Center, Tampa, Florida, USA.
• ⁴ Department of Dermatology, Specialist Clinic Bad Bentheim, Bad Bentheim, Germany.
• ⁵ Division of Dermatology, Washington University, St. Louis, Missouri, USA.
• ⁶ Department of Dermatology, Institute i+12, Hospital 12 de Octubre Medical School, University Complutense Madrid, Madrid, Spain.
• ⁷ Rochester Skin Lymphoma Medical Group, Fairport, New York, USA.
• ⁸ Department of Dermatology, MD Anderson Cancer Center, Houston, Texas, USA.
• ⁹ The Department of Dermatology and the O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham, Alabama, USA.
• ¹⁰ Medical Sciences, Kyowa Kirin, Inc, Princeton, New Jersey, USA.
• ¹¹ Medical Affairs, Kyowa Kirin, Inc, Bedminster, New Jersey, USA.
• ¹² Multidisciplinary Cutaneous Lymphoma Program, Stanford University, Stanford, California, USA.